Translational Research Laboratory for Urological Diseases, First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, PR China; Comprehensive Genitourinary Cancer Center, First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, PR China.
Department of Pharmaceutical Sciences, Texas Tech University Health Sciences Center School of Pharmacy, Amarillo, TX, USA.
Drug Discov Today. 2024 Aug;29(8):104057. doi: 10.1016/j.drudis.2024.104057. Epub 2024 Jun 4.
Antibody-drug conjugates (ADCs), from prototypes in the 1980s to first- and second-generation products in the 2000s, and now in their multiformats, have progressed tremendously to meet oncological challenges. Currently, 13 ADCs have been approved for medical practice, with over 200 candidates in clinical trials. Moreover, ADCs have evolved into different formats, including bispecific ADCs, probody-drug conjugates, pH-responsive ADCs, target-degrading ADCs, and immunostimulating ADCs. Technologies from biopharmaceutical industries have a crucial role in the clinical transition of these novel biotherapeutics. In this review, we highlight several features contributing to the prosperity of bioindustrial ADC development. Various proprietary technologies from biopharmaceutical companies are discussed. Such advances in biopharmaceutical industries are the backbone for the success of ADCs in development and clinical application.
抗体偶联药物（ADCs），从 20 世纪 80 年代的原型药物到 21 世纪的第一代和第二代产品，再到现在的多种形式，已经取得了巨大的进展，以应对肿瘤学方面的挑战。目前已有 13 种 ADC 获批用于医学实践，超过 200 种候选药物正在临床试验中。此外，ADC 已经发展成不同的形式，包括双特异性 ADC、前药 ADC、pH 响应 ADC、靶向降解 ADC 和免疫刺激 ADC。生物制药行业的技术在这些新型生物疗法的临床转化中发挥着关键作用。在这篇综述中，我们强调了促成生物工业 ADC 发展繁荣的几个特点。讨论了生物制药公司的各种专有技术。生物制药行业的这些进步是 ADC 在开发和临床应用中取得成功的支柱。
